StratifiCare Pte Ltd

StratifiCare specializes in providing insights into the body so that everyone everywhere can receive the best treatment. We achieve this through our predictive protein medical diagnostics and AI/ML.

We are currently developing a severe Dengue prediction test to advise on hospitalisation needs for 96 million Dengue patients across the globe, and a liver cancer radioembolization effectiveness prediction test to predict effectiveness for 1.6 million new liver cancer patients annually. Both products will enter clinical trial next year, and have gotten the interests of numerous international pharmas and diagnostic corporates to collaborate.

Majority of patients are currently being prescribed one-size-fits-all procedures or treatments based on guidelines without having advanced objective information on whether they are necessary or effective. This frequently results in patients having to undergo unnecessary hospitalisation and ineffective treatments, endure unnecessary side-effects, and waste precious recovery time and money.

Through the detection and measurement of different proteins - the execution molecules of biological functions in the body, and coupling this biological information with state-of-the-art artificial intelligence and machine learning, StratifiCare is able to provide doctors with information in advance on whether specific treatments are necessary or will be effective on individual patients.

While capitalising on a central infrastructure such as development laboratory, quality systems, procurement and HR for economies of scale, dedicated development and commercial teams are built around individual products to form decentralised business units. The eventual goal is to sell each business unit, and provide investors the flexibility to exit through share buyback using the proceeds or when StratifiCare IPO.